Autologous Focus Developing autologous cell therapies for solid tumors creates demand for patient-specific manufacturing, supply chain solutions, and regulatory support. Target sales opportunities include CDMO partnerships (process development, tech transfer, GMP manufacturing), analytical testing, and clinical supply services to accelerate trials.

Seed Financing A $10M seed round signals roadmap momentum and readiness to partner. Pursue milestone-based collaborations, platform licensing, and co-development deals with clear value share tied to clinical and manufacturing milestones.

Location Advantage San Francisco base provides access to top biotech talent, venture networks, and potential academic collaborations. Leverage proximity to CMOs/CROs, pharma, and academic partners to accelerate partnerships, tech transfer, and joint development.

Lean Team With a small team, the company will rely on outsourcing; frame BD offerings around end-to-end CDMO/CRO services, including manufacturing, quality systems, data management, and regulatory support to scale clinical programs.

Platform Focus Building a next-generation autologous cell therapy platform enables licensing or co-development with large biotech companies. Present platform-enabled concepts and offer enabling services (assay development, process optimization, GMP-ready workflows) to accelerate solid-tumor programs.